Regeneron Pharmaceuticals, Inc. (REGN) — Fair Value Analysis

Base-case fair value (P50): $721.80 · Current price: $654.27 · Verdict: Fairly Valued

The Verdict on REGN

Our latest Monte Carlo simulations indicate Regeneron Pharmaceuticals Inc (REGN) is Fairly Valued. With a current price of $654.27, REGN trades closely to our median fair value estimate (P50) of $721.80. This tight alignment implies a modest +10.3% from its current levels, suggesting the market price largely reflects its intrinsic value across thousands of simulated future scenarios. For investors, this means the stock isn't significantly mispriced, and immediate alpha potential based purely on valuation arbitrage appears limited.

How REGN stacks up against peers

While REGN's valuation appears fair, its underlying operational and financial health presents a notable contrast within its competitive landscape. Our analysis assigns REGN a weak quality tier relative to its sector, indicating potential challenges in its fundamental strength compared to industry counterparts. This quality assessment suggests that, despite the current fair valuation at $654.27 versus a median fair value of $721.80, there may be inherent operational or financial headwinds that could temper future performance or increase risk compared to higher-quality names in the pharma and biotech space.

What this means for investors

For investors considering REGN, the current Fairly Valued assessment, derived from our Monte Carlo models, means the market has likely priced in most known factors. With the current price of $654.27 positioned close to our median fair value of $721.80, the implied +10.3% is modest, making a strong case for a market-neutral stance rather than a compelling buy based on valuation alone. Furthermore, the weak quality tier highlights the importance of a deeper dive into the company's operational profile and financial resilience. FairCurve subscribers can access the full bear and bull case distributions for REGN and track its fair value as new fundamentals are released.